Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 01 2019 - 7:47AM
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical
dermatology company committed to the development and
commercialization of novel treatments that provide meaningful
benefit for people living with skin diseases, today announced that
Ted White, Verrica President and CEO, will present a business
overview of the company’s pipeline programs at the Bank of America
Merrill Lynch 2019 Healthcare Conference in Las Vegas, NV on
Tuesday, May 14, 2019 at 2:35 p.m. PT. and at the 2019 RBC Capital
Markets Global Healthcare Conference in New York, NY on Tuesday,
May 21, 2019 at 8:30 a.m. ET.
A live audio webcast of both events will be available in the
Investors/Events & Presentations section of the Verrica website
at http://www.verrica.com/. A webcast replay will also be available
on this website shortly after conclusion of the events for 30
days.
About Verrica Pharmaceuticals Inc.
Verrica is a medical dermatology company committed to the
development and commercialization of novel treatments that provide
meaningful benefit for people living with skin diseases. The
company’s late-stage product candidate, VP-102, is a potential
first-in-class topical therapy for the treatment of molluscum
contagiosum, a highly contagious viral skin infection affecting
approximately six million people, primarily children, in the United
States. There are currently no FDA-approved treatments for
molluscum. Following positive topline results from two pivotal
Phase 3 trials, a New Drug Application for VP-102 for the treatment
of molluscum is planned for the second half of 2019. VP-102 is also
currently in a Phase 2 trial for the treatment of common warts,
with an additional Phase 2 trial planned in genital warts. A second
product candidate, VP-103, is in pre-clinical development for
plantar warts. For more information, visit www.verrica.com.
Contacts
Chris DegnanChief Financial
Officer484.453.3300 ext. 103info@verrica.com
Patti BankManaging
DirectorWestwicke, an ICR
Company415.513.1284patti.bank@westwicke.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Sep 2023 to Sep 2024